21-05-2025
Biocon subsidiary and Yoshindo expand access to Ustekinumab Biosimilar in Japan
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon Ltd, announced that its commercial partner in Japan, Yoshindo Inc., has launched Ustekinumab BS Subcutaneous Injection [YD], a biosimilar version of the reference drug Stelara® (ustekinumab). This biosimilar ustekinumab, developed and manufactured by Biocon Biologics, is being marketed and commercialized in Japan by Yoshindo Inc.
Ustekinumab is a monoclonal antibody indicated for the treatment of psoriasis vulgaris and psoriatic arthritis (PsA). The biosimilar was developed and manufactured by Biocon Biologics and received approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) in December 2024.
This launch follows a settlement and licensing agreement signed in April 2024 between Biocon Biologics and Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson, allowing commercialization of Ustekinumab in Japan after regulatory approval.
Biocon Biologics had earlier launched the biosimilar Ustekinumab in the United States and Europe in February 2025, expanding its availability to help patients manage chronic inflammatory conditions.
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
